REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases.  "2026 is set to be a transformative ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

Understanding human gene function in living organisms has long been hampered by fundamental differences between species.

Research about LENN -- a patent-pending, virus-mimicking platform technology that targets bladder cancer cells with mRNA ...

Inflammation has to fight pathogens fast—but it can't get out of control. Researchers at the German Cancer Research Center ...

DUBLIN-- (BUSINESS WIRE)--January 13, 2026-- The "Biomedical and ICT Convergence Market by Technology, Solution and Region 2025-2030" report has been added to ResearchAndMarkets.com's offering.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, January 14, 2026. Let’s ...